Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm-Reference-Cited by-同舟云学术

Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm

Published:2020-04-02 Issue:5 Volume:80 Page:360-369
ISSN:0036-5513
Container-title:Scandinavian Journal of Clinical and Laboratory Investigation
language:en
Short-container-title:Scandinavian Journal of Clinical and Laboratory Investigation

Author:

Breimer Lars H.¹²,Nousios Petros¹,Olsson Louise¹,Brunnström Hans³

Affiliation:

1. Centre for Assessment of Medical Technology in Örebro, School of Health and Medical Sciences, Örebro University, Örebro University Hospital, Örebro, Sweden;

2. Department of Laboratory Medicine, Clinical Chemistry Division, Örebro University Hospital, Örebro, Sweden;

3. Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365513.2020.1742369

Reference94 articles.

1. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review

2. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer

3. PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

4. PD-L1 expression testing in non-small cell lung cancer

5. World Health Organization. Global cancer observatory: international agency for research on cancer. 2018. [cited 2019 Nov 13]. Available from: http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative efficacy of various CHIs combined with western medicine for non-small cell lung cancer: A bayesian network meta-analysis of randomized controlled trials;Frontiers in Pharmacology;2022-11-10

2. Thyroid dysfunction during PD‑1 inhibitor treatment in patients with cancer: Incidence and association with progression‑free survival;Oncology Letters;2022-07-13

3. PD ‐1/ PD‐L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity;IUBMB Life;2021-10-28

4. RANBP9 as potential therapeutic target in non-small cell lung cancer;Journal of Cancer Metastasis and Treatment;2020-06-24